|
Figure 6.
(a–c) Structural rearrangements in CDR2  ,
CDR3  and
CDR3 induced
by binding to mutant TPI–DR1. Bound E8, green; unbound E8,
magenta; HLA-DR1, gold; mutant TPI, gray. Residues from E8 and
DR1 involved in interactions with peptide are identified. (d)
Superposition of mutant TPI–DR1 in a form without bound ligand
(peptide, cyan; MHC, violet) and in complex with E8 (peptide,
gray; MHC, gold). Arrow indicates residues 55–59 of the
HLA-DR1 1
domain. (e) Conformational changes in TPI residues that contact
E8. Residues of TPI involved in interactions with E8 are
identified. Residue designations as in Figure 4.
|
